Abstract
INTRODUCTION Dementia pathogenesis begins years before clinical symptom onset, necessitating the understanding of premorbid risk mechanisms. Here, we investigated potential pathogenic mechanisms by assessing DNA methylation associations with dementia risk factors in Alzheimer’s disease (AD)-free participants.
METHODS Associations between dementia risk measures (family history, genetic risk score (GRS), and dementia risk scores (combining lifestyle, demographic and genetic factors) and whole-blood DNA methylation were assessed in discovery and replication samples (n=∼400 – ∼5,000) from Generation Scotland.
RESULTS AD genetic risk and two risk scores were associated with differential methylation. The GRS predominantly associated with methylation differences in cis but also identified a genomic region implicated in Parkinson’s disease. Loci associated with the risk scores were enriched for those previously associated with body mass index and alcohol consumption.
DISCUSSION Dementia risk measures show widespread association with blood-based methylation, which indicates differences in the processes affected by genetic and demographic/lifestyle risk factors.
Competing Interest Statement
AMM has received grant support from Pfizer, Eli Lilly, Janssen and The Sackler Trust. These sources are not connected to the current investigation. AMM has also received speaker fees from Janssen and Illumina. The remaining authors report no conflicts of interest.
Funding Statement
This work was supported by a Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) [104036/Z/14/Z] to AMM, KLE, CSH, DJP and others, and an MRC Mental Health Data Pathfinder Grant [MC_PC_17209] to AMM and DJP. REM is supported by an Alzheimer’s Research UK major project grant [ARUK-PG2017B-10]. KV is funded by the Wellcome Trust Translational Neuroscience PhD Programme at the University of Edinburgh [108890/Z/15/Z]. ADB would like to acknowledge funding from the Wellcome PhD training fellowship for clinicians [204979/Z/16/Z], the Edinburgh Clinical Academic Track (ECAT) programme. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, Edinburgh, Scotland and was funded by the UK’s Medical Research Council and the Wellcome Trust [104036/Z/14/Z]. DNA methylation profiling of the GS:SFHS samples was funded by the Wellcome Trust Strategic Award [10436/Z/14/Z] with additional funding from a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation [27404].
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses Rosie M. Walker: rwalke13{at}staffmail.ed.ac.uk; Mairead L. Bermingham: mairead.bermingham{at}igmm.ed.ac.uk; Kadi Vaher: kadi.vaher{at}ed.ac.uk; Stewart W. Morris: Stewart.Morris{at}igmm.ed.ac.uk; Andrew D. Bretherick: a.bretherick{at}ed.ac.uk; Yanni Zeng: zengyn5{at}mail.sysu.edu.cn; Carmen Amador: carmen.amador{at}igmm.ed.ac.uk; Konrad Rawlik: Konrad.Rawlik{at}roslin.ed.ac.uk; Kalyani Pandya: s1603705{at}sms.ed.ac.uk; Caroline Hayward: Caroline.Hayward{at}igmm.ed.ac.uk; Archie Campbell: archie.campbell{at}ed.ac.uk; David J. Porteous: david.porteous{at}igmm.ed.ac.uk; Andrew M. McIntosh: andrew.mcintosh{at}ed.ac.uk; Riccardo E. Marioni: Riccardo.Marioni{at}ed.ac.uk; Kathryn L. Evans: Kathy.Evans{at}igmm.ed.ac.uk
Declarations of interest: AMM has received grant support from Pfizer, Eli Lilly, Janssen and The Sackler Trust. These sources are not connected to the current investigation. AMM has also received speaker fees from Janssen and Illumina. The remaining authors report no conflicts of interest.
Data Availability
According to the terms of consent for GS:SFHS, access to data must be reviewed by the GS Access Committee (access{at}generationscotland.org).
